Can Novo Nordisk's Hims & Hers Deal Revive Its GLP-1 Momentum?

Key Takeaways Novo Nordisk partnered with HIMS to offer Ozempic and Wegovy via telehealth at self-pay prices nationwide.HIMS will stop advertising compounded GLP-1 drugs and transition patients to FDA-approved alternatives.Novo Nordisk shares also reacted to an FDA warning letter tied to post-marketing safety reporting processes.Earlier this week, Novo Nordisk (NVO) announced a partnership with telehealth platform Hims & Hers Health (HIMS) to expand access to its FDA-approved semaglutide medicines in the Un ...